Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Menges D, Piatti MC, Omlin A, Cathomas R, Benamran D, Fischer S, Iselin C, Küng M, Lorch A, Prause L, Rothermundt C, O'Meara Stern A, Zihler D, Lippuner M, Braun J, Cerny T, Puhan MA. Menges D, et al. Among authors: rothermundt c. Eur Urol Open Sci. 2023 Mar 22;51:26-38. doi: 10.1016/j.euros.2023.03.001. eCollection 2023 May. Eur Urol Open Sci. 2023. PMID: 37187724 Free PMC article.
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; Swiss Group for Clinical Cancer Research SAKK. Cathomas R, et al. Among authors: rothermundt c. Clin Cancer Res. 2012 Nov 1;18(21):6049-57. doi: 10.1158/1078-0432.CCR-12-2219. Epub 2012 Sep 12. Clin Cancer Res. 2012. PMID: 22977195 Clinical Trial.
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).
Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; Swiss Group for Clinical Cancer Research (SAKK). Templeton AJ, et al. Among authors: rothermundt c. Eur Urol. 2013 Jul;64(1):150-8. doi: 10.1016/j.eururo.2013.03.040. Epub 2013 Apr 6. Eur Urol. 2013. PMID: 23582881 Clinical Trial.
Abiraterone--what is wrong with the adrenal glands?
Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp NJ, Gillessen S. Schmid S, et al. Among authors: rothermundt c. Clin Genitourin Cancer. 2014 Aug;12(4):e133-7. doi: 10.1016/j.clgc.2014.01.008. Epub 2014 Feb 4. Clin Genitourin Cancer. 2014. PMID: 24583161 No abstract available.
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).
Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C. Joerger M, et al. Among authors: rothermundt c. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):167-72. doi: 10.1038/pcan.2015.8. Epub 2015 Mar 10. Prostate Cancer Prostatic Dis. 2015. PMID: 25753371
79 results